Year None20222021202020192018201720162015 Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022 November 14, 2022 at 7:00 AM EST Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) November 11, 2022 at 4:01 PM EST Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update November 10, 2022 at 4:01 PM EST Kezar Life Sciences to Participate in Two Upcoming Investor Conferences November 9, 2022 at 4:01 PM EST Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting November 3, 2022 at 10:00 AM EDT Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting October 14, 2022 at 7:00 AM EDT Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) October 6, 2022 at 4:01 PM EDT Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis October 3, 2022 at 4:01 PM EDT Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 September 29, 2022 at 4:05 PM EDT Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 2, 2022 at 4:30 PM EDT Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022 November 14, 2022 at 7:00 AM EST
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) November 11, 2022 at 4:01 PM EST
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update November 10, 2022 at 4:01 PM EST
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences November 9, 2022 at 4:01 PM EST
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting November 3, 2022 at 10:00 AM EDT
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting October 14, 2022 at 7:00 AM EDT
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis October 3, 2022 at 4:01 PM EDT
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 September 29, 2022 at 4:05 PM EDT
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 2, 2022 at 4:30 PM EDT